



SINGAPORE INSTITUTE OF ADVANCED MEDICINE HOLDINGS LTD.

(Incorporated in the Republic of Singapore on 24 November 2011)
(Company Registration Number: 201134046D)

ENTRY INTO A LOAN AGREEMENT

1. INTRODUCTION

The Board of Directors (the “**Board**” or “**Directors**”) of Singapore Institute of Advanced Medicine Holdings Ltd. (the “**Company**”, together with its subsidiaries, collectively, the “**Group**”) wishes to announce that the Company has on 20 December 2024 entered into a loan agreement (“**Loan Agreement**”) with Caterine Limited (the “**Lender**”). Pursuant to the Loan Agreement, the Lender has agreed to grant a loan in the principal amount of S\$5,000,000 (the “**Loan**”) to the Company, subject to the terms and conditions set out in the Loan Agreement.

2. SALIENT TERMS OF THE LOAN AGREEMENT

The salient terms of the Loan Agreement are as follows:

Principal Amount : S\$5,000,000

Maturity Date : The maturity date of the Loan shall be the date falling three (3) months from the date of the first disbursement of the Loan (“**Maturity Date**”). The Maturity Date may be extended for such period at the Company’s request, up to a maximum period of one (1) year from the date of the first disbursement of the Loan.

Repayment / Prepayment : The quantum of the Loan actually disbursed (“**Aggregate Indebtedness**”) shall be repaid on the Maturity Date.

The Aggregate Indebtedness and Interest may be repaid or prepaid by the Company (or any other person on its behalf), whether in full or part, at any time prior to the Maturity Date (without incurring any additional penalty), upon giving seven (7) days’ notice to the Lender prior to the repayment of the Aggregate Indebtedness and Interest.

Interest : Interest will accrue on the outstanding Aggregate Indebtedness at the rate of 6.7% per annum (“**Interest**”), commencing on the actual date of disbursement of the Aggregate Indebtedness until the Maturity Date or the repayment or settlement of the Aggregate Indebtedness, whichever is the earlier.

Purpose of the Loan The Loan shall be used by the Company to finance the growth of the Company’s business and/or for general working capital purposes.

Event of Default Upon the occurrence of any of (i) the Company failing to make punctual payment of any part of the Aggregate Indebtedness and Interest when such amount falls due, (ii) the Company’s default of any covenant or agreement in the Loan Agreement which is not cured within 30 business days, (iii) the Company making a general assignment for the benefit of creditors or consenting to the appointment of a receiver, liquidator, custodian, or similar official of all or substantially all of its properties, or if any such official is placed in control of such properties, or (iv) the Company commencing any action or proceeding or taking advantage of or filing under any insolvency statute, seeking to have an order for relief entered with

respect to it or seeking adjudication as insolvent, or seeking reorganisation, arrangement, adjustment, liquidation, dissolution, or other relief with respect to it or its debts (each an “**Event of Default**”), the Company shall be obliged, at the option of the Lender serving fourteen (14) days’ prior written notice on the Company to repay the entire Aggregate Indebtedness and Interest in full.

3. INFORMATION ON THE LENDER

Shareholders should note that the information relating to the Lender in this paragraph and elsewhere in this announcement was provided by the Lender. The Company and the Directors have not independently verified the accuracy and correctness of such information.

The Lender is a company incorporated in the British Virgin Islands, and is principally engaged in investment holdings. The Lender is a wholly-owned subsidiary of Casi Management Sdn. Bhd., which is in turn a company incorporated in Malaysia and is principally engaged in investment holding. The Lender was introduced to the Group through its business contacts and connections.

As at the date of this announcement, the Lender and its ultimate beneficial owners does not hold, whether directly or indirectly, any Shares in the Company. To the best of knowledge of the Directors, the Group, the Company, its Directors and substantial shareholders do not have any connection (including business relationship) with the Lender, save as stated in the above paragraph.

4. RATIONALE FOR THE LOAN

Under the Loan Agreement, the Loan shall be used by the Company to finance the growth of the Company’s business and/or for general working capital purposes. The Directors are of the view that the Company’s entry into the Loan Agreement is beneficial to the Group as the Loan will improve the Group’s cash flow to meet anticipated general working capital requirements (including meeting general overheads, financing requirements and other operating expenses).

5. INTERESTS OF DIRECTORS AND CONTROLLING SHAREHOLDERS

None of the Directors or controlling shareholders of the Company and their respective associates has any interest, direct or indirect, in the Loan Agreement, other than through their respective shareholdings (if any) and/or directorships in the Company.

The Company will make further announcement(s) in relation to the Loan Agreement, as and when required.

BY ORDER OF THE BOARD

Dr Djeng Shih Kien
Executive Director and Chief Executive Officer
20 December 2024

Singapore Institute of Advanced Medicine Holdings Ltd. (the “**Company**”) was listed on Catalist of the Singapore Exchange Securities Trading Limited (“**SGX-ST**”) on 16 February 2024. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the “**Sponsor**”).

This announcement has been reviewed by the Sponsor. It has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms. Ng Shi Qing, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.